Fridays Loser Stock (ELLI, DNDN, ATHX)

Los Angelas, CA -- (SBWIRE) -- 01/11/2013 -- The mortgage software and services provider Ellie Mae (NYSE:ELLI)has an 87% sales growth rate for last quarter as it shifts customers over to its software-as-a-service, or SAAS model. Rising mortgage originations, thanks to a slowly improving housing market, have helped too. Its shares were down 1.9% Wednesday to 27.52. The stock tried to break out of its consolidation on Jan. 2, but quickly fell back. It continues to build a handle. Shares of Ellie Mae, Inc. (NYSE:ELLI) are trading at $25.26 and is -1.94% from its 50-day Moving Average price of $25.7588 and +3.65% from its 200-day Moving Average price of $24.3703. The average trading volume is 647910 shares and its market capitalization is $648.1M.

How Should Investors React To ELLI Now? CHECK HERE

Dendreon's (NASDAQ:DNDN) performance hasn't met lofty investor expectations, there is still real reason to be excited. In this video, Motley Fool health care analyst David Williamson discusses Dendreon's potentially revolutionary prostate cancer vaccine, Provenge, and how it can capitalize on the enormous prostate cancer market. Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as Provenge became a lightning rod of debate.

Receive The Update Via Email About DNDN: Free Sign Up Here

Athersys, Inc. (NASDAQ:ATHX) is a small cap biotech stock that has the potential for blockbuster returns. The company has a deep pipeline in multiple markets all that can potentially generate billions in sales. Pfizer (PFE) is currently a partner for one of these opportunities. Before I go into specifics regarding Athersys, Inc.'s potential, I briefly want to discuss it's valuation and capital burn rate. Athersys, Inc.'s stock price decline in fourth quarter of 2012 was attributed to a stock offering. Since then the stock price has been steady and is now starting to trend upward. At the current price, the company's market cap is approximately $60M with $30M in cash. The company's burn rate is approximately $4M per quarter so the current cash position should be sufficient for two more years. With a $60M market cap and $30M in cash, Athersys, Inc.'s pipeline is valued at the remaining $30M. So why is Athersys an undervalued spec company with high potential?

Are these stocks a buy or sell? Free Sign Up Here For Actual Advice

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com